6/3, 10:45 AM EST/9:45 AM CDT , A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013). Authors: Vadim Spektor. meetings.asco.org/2025-asco-an...

6/3, 10:45 AM EST/ 9:45 AM, Does the Road to Cure Myeloma End with Minimal Residual Disease?. Discussant: Suzanne Lentzsch, MD, PhD. meetings.asco.org/2025-asco-an...

6/2, 8:00 AM CDT, Efficacy and safety of dordaviprone (ONC201) in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients.
Author: Aya Haggiagi
meetings.asco.org/2025-asco-an...

6/2, 9:45 AM CDT, A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas.
Author: Alexander Wei. meetings.asco.org/2025-asco-an...

6/2, 8:00 AM CDT, Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.
Author: Rajshekhar Chakraborty. meetings.asco.org/2025-asco-an...

6/2, 8:00 AM CDT, Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial.
Author: Rajshekhar Chakraborty. meetings.asco.org/2025-asco-an...

6/2, 8:00 AM CDT, Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.
Author: Rajshekhar Chakraborty. meetings.asco.org/2025-asco-an...

5/31, 1:15 PM CDT. Phase I/Ib study of INAVO alone and in combination with endocrine therapy ± palbociclib in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer.
Author: Melissa Accordino
meetings.asco.org/2025-asco-an...

5/31, 3:00 PM CDT. Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.
Author: Ran Reshef
meetings.asco.org/2025-asco-an...

5/31, 3:00 PM CDT. Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C/EBPβ-dependent mesenchymal cell transition and immunosuppressive M2 macrophage polarization.
Presenter: Fabio Massaiti Iwamoto
meetings.asco.org/2025-asco-an...

5/31, 8:00 AM CDT, Association between allostatic load and breast radiomic features among diverse women undergoing screening mammography.
Presenter: Sara Wallam
meetings.asco.org/2025-asco-an...

5/30, 2:45 PM , A phase 2 study of pemigatinib for pre-treated glioblastoma or other gliomas with activating FGFR1-3 alterations: Results from FIGHT-209.
Author: Andrew Lassman.
meetings.asco.org/2025-asco-an...

5/30, 2:45 PM , A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).
Author: Ran Reshef.
meetings.asco.org/2025-asco-an...